Drug
Olezarsen clinical trials
Also written ISIS 678354 and AKCEA-APOCIII-LRx.
- studies test it
- 13
- open now
- 1
- in phase 3
- 8
- first study started
- 2007
Keep track of what changes. Save the olezarsen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2022 (6)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 6 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 8
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Ionis Pharmaceuticals, Inc. (10) · Panacea Biotec Ltd (2) · Akcea Therapeutics (1)
Studies
Open first, then newest update. How each study uses olezarsen is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric ParticipantsRecruitingPhase 3Ionis Pharmaceuticals, Inc.NCT07727538Written as Olezarsen
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe HypertriglyceridemiaCompletedPhase 2Ionis Pharmaceuticals, Inc.NCT05355402Written as Olezarsen
- A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe HypertriglyceridemiaCompletedPhase 3Ionis Pharmaceuticals, Inc.NCT05610280Written as Olezarsen
- A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe HypertriglyceridemiaCompletedPhase 3Ionis Pharmaceuticals, Inc.NCT05079919Written as Olezarsen
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)Active, not recruitingPhase 3Ionis Pharmaceuticals, Inc.NCT05130450Written as Olezarsen
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With VolanesorsenActive, not recruitingPhase 3Ionis Pharmaceuticals, Inc.NCT05185843Written as Olezarsen
- CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)Active, not recruitingPhase 3Ionis Pharmaceuticals, Inc.NCT05681351Written as Olezarsen
- A Study of Olezarsen Administered Subcutaneously to Participants With Severe HypertriglyceridemiaCompletedPhase 3Ionis Pharmaceuticals, Inc.NCT05552326Written as Olezarsen
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)CompletedPhase 3Ionis Pharmaceuticals, Inc.NCT04568434Written as Olezarsen
- A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult ParticipantsCompletedPhase 1Ionis Pharmaceuticals, Inc.NCT05579860Written as Olezarsen
- Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)CompletedPhase 2Akcea TherapeuticsNCT03385239Written as ISIS 678354
- Bioequivalence Study of Cyclosporine 100mg Capsule Under Fasting ConditionCompletedNot applicablePanacea Biotec LtdNCT01080560Written as Cyclosporine Capsules USP (Modified) 100 mg
- Bioequivalence Study of Cyclosporine 100mg Capsule Under Fed ConditionCompletedNot applicablePanacea Biotec LtdNCT01080586Written as Cyclosporine Capsules USP (Modified) 100 mg
Codes
What other systems call olezarsen · ClinicalTrials.gg INT002102
- MeSH (NLM) C000731151olezarsenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) S3RS2SA30LOLEZARSENConfirmed FDA, NLM
- NCI Thesaurus C180652OlezarsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731151 | olezarsen | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | S3RS2SA30L | OLEZARSEN | Confirmed FDA, NLM |
| NCI Thesaurus | C180652 | Olezarsen | One source FDA |
Also registered as olezarsen sodium (UNII NSY2BY6PSB).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.